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Abstract
Introduction: Mastocytosis is a rare disease consisting of a group of disorders characterized by a pathologic increase in 
the number of mast cells in one or more organ system. Treatment is symptomatic. Oral sodium cromoglicate (SCG) is 
the only treatment licensed for the treatment of mastocytosis. In this case we report how in a mastocytosis patient 
being treated with H1 and H2 antihistamines, and oral sodium cromoglicate, the addition of inhaled sodium 
cromoglicate resulted in further improvement. This is the first report of this use of the drug in this disease.
Case presentation: The subject is a Caucasian woman aged 40 years. Symptoms of mastocytosis began when she was 
aged 13 years, but the diagnosis was not made until after her first pregnancy aged 33 years. Symptoms improved with 
H1 and H2 antihistamines, and oral sodium cromoglicate, but it required the addition of inhaled sodium cromoglicate to 
produce further improvement, specifically in the symptoms of bone pain, fatigue and headache. Doses of oral sodium 
cromoglicate had to be increased if challenged with a food to which the subject was sensitive. Doses of inhaled 
sodium cromoglicate had to be increased during the menstrual period.
Conclusions: Patients suffering from the rare disease of mastocytosis have symptoms affecting many body systems. 
Symptoms result from the release of inflammatory mediators from mast cells. Sodium cromoglicate, a drug that 
reduces the release of mediators from mast cells, is effective in controlling gastrointestinal symptoms, but less effective 
in those affecting other body systems. In this case report we have shown that the addition of inhaled sodium 
cromoglicate controls the symptoms of bone pain, fatigue and headache and also that the doses have to be increased 
during the menstrual period.
Introduction
Mastocytosis (SM) consists of a group of clonal disorders
characterized by a pathologic increase, usually low, in the
number of mast cells in one or more organ system. The
most common form of SM is indolent SM (ISM) compris-
ing around 80% of cases. Patients with SM have symp-
toms related to tissue responses to the release of mast cell
(MC) mediators, infiltration of tissues by MC or both.
MC mediator-related symptoms are heterogeneous and
can appear either spontaneously or in response to certain
triggers. The consequence of the release of mediators is a
range of symptoms of variable severity, from mild to life
threatening and can involve the skin, the gastrointestinal
tract, the skeletal system, cardiovascular system, central
nervous system and even induce constitutional symp-
toms [1].
A curative treatment of SM is not available. Pharmaco-
logical treatment is symptomatic and in most cases this
consists of a rationale combination of MC blockers, such
as oral sodium cromoglicate (SCG), H1 and H2 antihista-
mines while other therapies such as corticosteroids, and
leukotriene antagonists are less frequently employed.
SCG is a chromone, initially developed as an inhaled
dry powder for the treatment of asthma [2], and subse-
quently as a nasal spray for allergic rhinitis, eye-drops for
allergic conjunctivitis and oral capsules, sachets and oral
aqueous solution for food allergy. In the USA the oral
solution (Gastrocrom™) is licensed for the treatment of
SM.
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lar weight 512. It is poorly absorbed through all body sur-
faces apart from the bronchial mucosa where the entire
drug reaching the bronchial mucosa after inhalation is
absorbed. The inhaled product, is available in various
forms, a capsule containing 20 mg of SCG powder,
metered dose inhalers (MDIs) delivering either 1 mg/puff
or 5 mg/puff and aqueous solution for nebulization.
Approximately 10.4% of the inhaled dose from capsules is
deposited in the lung all of which is absorbed [3].
When administered orally between 0.8% and 1% is
absorbed systemically. The drug is not metabolized, most
is excreted unchanged during the first 24 hours after
administration, half in the feces and half in the urine [4].
The first report of the use of SCG administered orally
for the treatment of SM was in 1974 [5]. There have been
four controlled trials of oral SCG in SM [6-9]. The dose of
SCG used varied between 400 mg/day to 800 mg/day. In
some of these trials the addition of SCG resulted in the
improvement of both gastrointestinal and non-gastroin-
testinal symptoms. In others only the gastrointestinal
symptoms were improved.
Symptoms such as bone pain and headache that result
from mediator release from MCs in the bone marrow and
meninges will require higher blood levels of SCG than
that achieved by oral SCG. We report on a case using
inhaled SCG to achieve these ends.
Case presentation
Patient
Our patient is a Caucasian woman aged 40 years. Symp-
toms now recognized due to SM occurred from the age of
13 years but were not severe enough to seek advice or a
diagnosis. Symptoms became more severe after the birth
of her first child. These consisted of body pain, stomach
pains, headache, flushing, itchy spots, severe fatigue and
difficulty in concentration. The diagnosis of ISM was
made a year later following a bone marrow biopsy. Ini-
tially treatment was an antihistamine only. Despite this
she continued to be very fatigued, with daily bone, muscle
and head pain. She also had severe gastrointestinal symp-
toms, diarrhea and abdominal pain. At this time her
serum tryptase was 49 μg/mL. She was referred to one of
us (HH). At that time her treatment was changed to
desloratadine 5 mg tablets, one to two daily, lanzoprazole
15 mg tablets, when needed, and acetylsalicylic acid 500
mg tablets, up to two tablets four times daily, and SCG
oral solution (Lomudal GI™), 200 mg four times daily.
This change in treatment resulted in an improvement in
symptoms, particularly the gastrointestinal.
However, she still had symptoms specifically of bone
pain and headache, it was decided to try the effects of
adding inhaled SCG to her current treatment.
In order to monitor the progress of symptom control
with the introduction of inhaled SCG, our patient
recorded the severity each day of 21 symptoms using a
daily diary card (see Additional File 1). The severity of
symptoms was recorded using a zero to four scale; 0 = no
symptoms, 1 = mild, 2 = moderate, 3 = severe, 4 = very
severe. Completed diary cards were returned to one of us
(AME) via email on a regular basis together with any
comments and advice on any dosage changes of the SCG
products communicated in the same way. Our patient
was also seen by one of us (HH) regularly at a specialist
hospital clinic. At each visit blood was taken for measure-
ments of serum tryptase.
Inhaled SCG was administered using gelatine capsules
(Lomudal Caps.) each containing 20 mg of pure SCG
powder. The initial dose was 20 mg (one capsule) inhaled
four times daily using an Eclipse Inhaler.
Results
The observations reported here were made over a period
of five and a half months during which the subject kept
daily diary cards recording symptom severity. For the first
three days she remained on existing therapy.
Figure 1 shows the mean daily diary card scores for the
six symptom groups both for the three days before the
introduction of inhaled SCG (solid columns) and for the
following eight weeks at a dose of 80 mg/day adminis-
tered as 20 mg four times daily. It can be seen that there
was an improvement in all symptoms, but the improve-
ment in bone pain (Skeletal Group) was not apparent
until after six weeks of treatment. Interestingly a worsen-
ing of most symptoms occurred during weeks three and
four of this period, the week before and the week of her
monthly menstrual period.
Figure 2 shows the mean daily symptom scores for the
two weeks before her next menstrual bleed, the week of
the bleed and the week following. During the week of the
menstrual bleed, bone pain (Skeletal symptoms) was
worse, mean ± standard deviation (SD) 2.57 ± 0.53.
On the basis of these findings she was advised to
increase the dose of oral SCG on any day she ate a food
which she knew might trigger a reaction; in addition to
increase the dose of inhaled SCG to two capsules four
times a day (160 mg/day) from just before and during the
expected menstrual period.
She followed this advice over her next menstrual
period. As depicted in Figure 3 up to two days before her
menstrual bleed she had been scoring zero for bone pain,
this worsened during the days of the menstrual bleed but
the increase in severity was less than when she did not
increase the dose of inhaled SCG, mean (SD) score for
bone pain 1.17 (0.4).
She had abdominal pain and diarrhea on one day dur-
ing the menstrual bleed and increased the dose of oral
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day and no diarrhea after two days.
The time period covered by this report was for a five
and half month period from June to November. In the
spring of that year her serum tryptase was 52 μg/mL; in
the autumn of that year it was 50 μg/mL and in the spring
of the following year was 44 μg/mL.
Our patient has continued to use this treatment up to
the time of this report.
Discussion
In this case report we describe the management and
improvement in symptoms of a patient with ISM when
inhaled SCG is added to existing treatment.
Oral SCG has been used in the management of SM for a
number of years, with benefit, but there has been little
work examining the optimal dose. Our patient found that
for most of the time a dose of 800 mg/day was adequate
to control her gastrointestinal symptoms, but she had to
increase the dose to 1200 mg/day should she eat some-
thing that might trigger an exacerbation. In a study in
food sensitive patients it has been shown that single doses
ranging from 100 to 800 mg were needed to block a reac-
tion to food challenge [10]. Single doses of 500 mg have
been used to prevent the effects of food challenge [11].
The symptoms that improved with the introduction of
inhaled SCG at a dose of 20 mg four times daily were
bone pain, headache and fatigue. On one occasion when
our patient reduced the dose to 20 mg three times daily
for two days, bone pain returned on the second day, and
fatigue and headache the day after. This also happens if
she forgets to increase the dose during her monthly men-
strual periods.
We suggest that the worsening of specific symptoms
when the dose of inhaled SCG was reduced supports that
the effect observed is drug related and not a placebo
effect.
The worsening of symptoms during the menstrual
cycle, possibly related to MC activation has been
reported in other cases of ISM. An Interactive Case
Report in the British Medical Journal describes a woman
who had hypotensive shock at the onset of menstruation
as one of the symptoms of ISM [12].
We can hypothesize that bone pain results from the
release of mediators from MCs in the bone marrow.
It was therefore considered necessary to try to achieve
maximum blood levels of SCG. This is more likely with
inhaled SCG than with increasing the dose of oral SCG.
After a single oral dose of 300 mg peak blood levels of
10.75 ± 2.54 ng/mL in healthy subjects and 6.02 ± 1.48
ng/mL in food allergic patients have been reported [13].
Figure 1 Mean symptom scores. Mean symptom scores recorded before the introduction of inhaled sodium cromoglicate and for the first eight 
weeks after introduction. Symptoms (22 in total) are grouped according to organ systems. Symptoms are recorded daily by patient using a 0-4 scale. 
Columns are mean scores for two weeks. Error bars are standard error of means. Key: solid black columns - before the introduction of inhaled sodium 
cromoglicate. First eight weeks after the introduction of inhaled sodium cromoglicate; solid white columns - weeks 1 and 2; columns with horizontal 
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have been conducted using the Spinhaler. This provides
peak blood levels of 42 ± 26 ng/mL in healthy volunteers
[14].
In arriving at our conclusions that inhaled SCG can
improve the symptoms of SM, we relied on the changes in
subjective symptom severity recorded by a single patient.
Whilst this is not evidence from a controlled trial we
believe that patient-related outcomes (PROs) are impor-
tant and useful data in deciding on the optimal use of a
treatment. An editorial in Clinical & Experimental
Allergy stated that symptom scores are an example of
PROs and both the Federal Drug Administration (FDA)
and the European Medicines Agency (EMEA) underwrite
the importance of PROs in the study of new drugs [15].
We therefore believe that the changes reported in diary
card symptom scores are reliable information confirming
drug efficacy.
Serum levels of tryptase did fall over the period covered
by this report. The reduction was small. It is not known if
this was due to the introduction of inhaled SCG
Oral SCG alone was not adequate to control the bone
pain, fatigue and headaches. It was necessary to add
inhaled SCG and to double the dose during parts of the
menstrual cycle for this to be achieved.
Conclusions
SM is a rare condition that results in symptoms in multi-
ple organ systems. Symptoms result from the release of
inflammatory mediators from MCs which are present in
large numbers. The release of mediators can be reduced,
also reducing the severity of the symptoms by the use of
SCG. In this case report we have shown that the effect of
SCG is dose dependent and also dependent on the
method of administration. For optimal symptom control
both oral and inhaled SCG is required. This is important
information for physicians dealing with this disease.
Patient's perspective
Since I've been around 13 years old I had problems with
stomach and back pains. Off and on I tried to go to the
doctor to get help, but never got any other help than tem-
porary medications. Soon I realized that going to the doc-
tor was a waste of time since they couldn't help me either
way, so I bought my medications myself on the local
pharmacy and went on that way. Looking at things now I
clearly can see that my illness has been worse in periods
of time. Even during my teens I had longer periods with
fatigue and such, which went away eventually. All this
time I've been able to go to school/work though. In 2002 I
got pregnant and gave birth to a child. The pregnancy
was wonderful. I lost almost all my symptoms (which I
then didn't know was symptoms of this) and felt very
healthy and energized, with no pain stomach problems.
Figure 2 Mean symptoms scores. Mean symptom scores covering a four week period commencing ten weeks after starting inhaled sodium cromo-
glicate treatment. Dosage of inhaled sodium cromoglicate 80 mg/day throughout. Menstrual bleed occurred during Week 3 of this four-week period. 
N.B. 'y' axis shows 0-3 range of 0-4 scale. Key: solid black columns - Week 1; columns with vertical lines - week 2; columns with horizontal lines - week 
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Page 5 of 6After giving birth I felt well during the first months but
after that things went much worse than before the preg-
nancy. I suffered from stomach pain with diarrhea, head-
ache, back pain, serious fatigue, some irritability,
sensitivity in food and smells, itching, flushing and so on.
Always after my monthly period I had at least a week
when I was more or less unable to do things at all. By the
time I was supposed to go back to work it was no longer
possible so I went into a long period of "sick leave". Dur-
ing this time I went to non-specialists that weren't very
interested in my case. I got the feeling they thought I
made it up.
After a while I finally went to see a doctor, this time I
went to a dermatologist because of spots that I had all
over my body which were itching terribly. I've had those
spots since I was two years old but in my younger years I
only had them on my feet. Now they were over my whole
body, in some places very tightly together. The dermatol-
ogist easily saw that this was urticaria pigmentosa. When
I told her about the other symptoms she told me that
there was a systemic possibility when you had these spots
on your skin but that she didn't think I had that since it
was so uncommon. So I went away from there with just
an antihistamine as a help for the itching. After some
time I managed to persuade her to send me to a bone
marrow biopsy which I finally did in December 2003 and
I got the results in January 2004. The results were that my
problem was mastocytosis.
The doctor who made the biopsy told me that I didn't
need any medications for this and that I couldn't feel the
way I did because of it. The dermatologist refused to send
me to a specialist for mastocytosis since she had the same
thoughts about how I felt as the biopsy doctor.
After doing my own research on the Internet (I natu-
rally didn't feel any better just because they said I
shouldn't feel the way I did), I found the names of a cou-
ple of doctors here that worked with patients with masto-
cytosis. One of the doctors in periods of the year worked
very close by where I live. After finding these names and
some information about mastocytosis I turned to a medi-
cal board which have as a task to make sure that people
get the right treatment, they contacted my dermatologist
and made sure she sent me to this specialist.
After waiting for about two months I finally got to see
this doctor, Dr Hans Hagberg. He had a completely differ-
ent view on how I could feel, since actually meeting some
Figure 3 Mean symptom scores. Mean symptom scores covering a three-week period commencing 20 weeks after starting inhaled sodium cromo-
glicate treatment. Menstrual bleed occurred during week 2 of this 3-week period. Dosage of inhaled SCG: 80 mg/day during week 1, 160 mg/day dur-
ing week 2, 80 mg/day during week 3. N.B. 'y' axis shows 0-2 range of 0-4 scale. Key: columns with horizontal lines - week 1; columns with vertical lines 
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Page 6 of 6patients with this illness. After seeing him a couple of
times he prescribed sodium cromoglicate to me. At first
as a drinkable medication and then in addition as inhaled
powder. It took about a month and I was feeling much
better.
I was being able to have a social life and also going back
to work - full time! I was very, very happy over this, espe-
cially since I never thought I'd be able to work again or
even feel well again. I still had my symptoms but a lot less
severe.
After talking to Dr Alan Edwards around the same time
I went back to work we discussed me being in his study. I
filled in the report cards daily for several months. During
this period a pattern became very clear. During my
monthly period I had about two weeks with a very high
increase in symptoms and specially the fatigue. I got the
advice to increase the inhaled sodium cromoglicate,
which I did and my symptoms over all, including the
fatigue, almost vanished.
With the help from Dr Alan Edwards, Dr Hans Hagberg
and sodium cromoglicate I went from being unable to
work and having a social life, to working full time and
more, with traveling in work and a very rich social life. I
still have minor symptoms off and on, and I still have
fatigue around my monthly period but I can handle it
now and keep it under control
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